# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

> **NCT05367661** · PHASE1 · TERMINATED · sponsor: **Chinook Therapeutics, Inc.** · enrollment: 88 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CHK336
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05367661
- **Lead sponsor:** Chinook Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-08
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367661, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05367661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*